PharmaPoint: Macular Edema - Global Drug Forecast and Market Analysis to 2026

News provided by

Feb 07, 2018, 09:50 ET

NEW YORK, Fev. 7, 2018 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p05304781

Summary
Macular edema (ME) is a condition where fluid and protein deposits accumulate on the macula, causing it to swell, leading to vision deterioration and loss. There are three main types of ME that warrant pharmacological treatment: diabetic macular edema (DME), macular edema following branch retinal vein occlusion (ME-BRVO), and macular edema following central retinal vein occlusion (ME-CRVO). The arrival of anti-vascular endothelial growth factor (VEGF) therapy revolutionized the treatment of ME and has quickly established itself as the gold standard of care.

Pharmaceutical sales within the diabetic macular edema (DME) and macular edema following retinal vein occlusion (ME-RVO) markets are expected to see significant growth, with an overall Compound Annual Growth Rate (CAGR) of over 6.5% over the forecast period from 2016-2026.With about 65% of the overall ME market, the US is clearly the most dominant market within the 7MM, generating around $2.4B in sales in 2016. This trend is expected to continue, and by the end of the forecast period, the US will account for around 70% of the 7MM market, generating over $4.5B in pharmaceutical sales.

We forecasts four pipeline drugs to launch in the ME market during the forecast period. Despite all four launching in the US, only two will launch in the 5EU and none are expected to become available in Japan within the next 10 years.

Of the pipeline drugs expected to launch in the US, Luminate, a novel integrin peptide being developed by Allegro in combination with Avastin, is forecast to generate the highest in sales in the DME market, with a 2026 value of over $600M. Its high sales will be attributed to its first-in-class status and high cost of therapy.

Anti-VEGF therapies represent the gold standard of care for ME across the 7MM, amassing $3.5B in global sales in 2016. Eylea was responsible for 63% of anti-VEGF sales and 60% of total global sales, with a 2016 value of over $2 Billion.

Eylea's hold over the market is expect to continue as physicians favor this drug over rival anti-VEGF therapy Lucentis due to its perceived higher efficacy, easier dosing schedule, and lower treatment cost in certain markets. Sales of this blockbuster drug are forecast to peak at around $4.2B in 2025, after which sales will decline due the likely entry of cheaper biosimilars across the 7MM.

The report "PharmaPoint: Macular Edema - Global Drug Forecast and Market Analysis to 2026", provides the overview of macular edema, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following -
- Annualized macular edema therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (DME, ME-BRVO and ME-CRVO) forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the macular edema therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for macular edema therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global macular edema therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Roche/Genetech, Novartis, Regeneron, Bayer, Santen Allergan

Scope
- Overview of macular edema, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized macular edema therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (DME, ME-BRVO and ME-CRVO) forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the macular edema therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for macular edema therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global macular edema therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global macular edema therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global macular edema therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Read the full report: https://www.reportlinker.com/p05304781

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001